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Abstract
Background: It is unclear whether EDSS is responsive to disability worsening in advanced MS.
Objective: To explore the dynamics of disability worsening in persons with advanced-stage MS (EDSS
5.5) using three disability worsening definitions (EDSS, Rivermead Mobility Index (RMI), 9-Hole Peg
Test (9-HPT)).
Methods: EDSS-, RMI- and 9-HPT-based disability worsening were assessed over a minimum of two
years in a cohort of 286 persons with advanced MS attending inpatient rehabilitation using Kaplan-
Meier Curves and multivariable Cox regression. Furthermore, the correspondence between EDSS-,
RMI- and 9-HPT-based disability worsening was analyzed.
Results: Disability progression was observed in 49% (9-HPT), 52% (EDSS) and 53% (RMI), with
9-HPT-based worsening slightly lagging behind. The Multiple Sclerosis Severity Score (MSSS) was
the only consistent factor predicting disability worsening based on all three definitions (EDSS: hazard
ratio 1.48 [1.30;1.68]; RMI: 1.12 [0.99;1.27]; 9-HPT: 1.36 [1.18;1.57]). Correspondence between EDSS
and the other definitions (9-HPT and RMI) was 44.3% and 55.7% at time of EDSS progression and 65.1%
and 72.5% overall, respectively.
Conclusion: In persons with advanced-stage MS, half still developed disability worsening in different
functional systems over a median of 6 years. MSSS seems a valid predictor for disability worsening in
all three outcome measures in advanced MS.
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Introduction
MS is known to lead to progressive impairments
over time. However, the great variability of disease
expression with respect to symptomatology and pro-
gression speed hamper individual predictions of the
future disease course. This multi-faceted disease pre-
sentation also entails the lack of a universally
accepted measurement scale to comprehensively
describe functionality or disability status. For exam-
ple, the widely employed Extended Disability Status
Scale (EDSS) is heavily geared towards the assess-
ment of gait mobility, thereby ignoring upper limb
functions or symptoms such as fatigue or depression.
The EDSS is further criticized because it suffers
from substantial inter-rater variability.1,2 Moreover,
most instruments to measure impairments, including
EDSS, were developed in persons with mild to mod-
erate MS, and hence the understanding of disease
progression in persons in advanced stages or with
a more severe disease course is still partial.3–10
To make further progress in understanding different
disease course expressions, it is important to discern
how established impairment measurements behave
across the full spectrum of disease presentation
(i.e. from mild to very severe impairments), which
only few studies have attempted so far.11 This aspect
is particularly pertinent for persons with (primary or
secondary) progressive multiple sclerosis and is
gaining relevance with the advent of new specifi-
cally targeted medications. Treatment response
monitoring requires outcome measures that are
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responsive in persons with MS (PwMS) with more
advanced impairments. Against this background, this
study’s aims were as follows.
First, we aimed to describe and assess the dynamics
of disability worsening based on EDSS and two
other outcome measures (nine-hole peg test (9-
HPT), Rivermead Mobility Index (RMI)) in persons
attending a Swiss in-patient neuro-rehabilitation
with EDSS 5.5.10
Second, we sought to compare the dynamics and
convergence of the two disability assessments rela-
tive to EDSS. These analyses were performed at two
time-points: at time of EDSS-based disability wors-
ening and at the last available follow-up.
Methods
Setting of data collection
The data was collected at the Berner Klinik Montana
in Crans-Montana, Switzerland from 1992 to 2015.
The Berner Klinik is a rehabilitation clinic with
around 250 PwMS in in-patient rehabilitation each
year. This corresponds to about 35% of all MS-
related in-patient rehabilitations in Switzerland.
The entire spectrum of PwMS is covered with a pre-
ponderance of the progressive forms. The MS neuro-
rehabilitation consists generally of a three-week
program with individualized therapy consisting of
a combination of physiotherapy, occupational thera-
py, speech therapy, and nutritional counselling,
among others. The Berner Klinik is a member of
the rehabilitation in multiple sclerosis (RIMS)
which is a European network for best practice and
research in the rehabilitation of MS. [REF: Website
https://www.eurims.org/]
Outcome measures
The Berner Klinik applies a battery of tests to assess
the progress made during the rehabilitation stay.
Three outcome measures were selected for the pre-
sent study because they were systematically assessed
in all in-patient rehabilitation stays. The first was the
EDSS as the most used progression measure in clin-
ical research. It is responsive towards gait mobility
and was assessed by a neurologist.1,2,10 The nine-
hole peg test (9-HPT) was the second, a manual dex-
terity tool executed for both hands individually and
part of the MSFC.4,12 The third was the Rivermead
Mobility Index (RMI), which assesses whether spe-
cific mobility tasks can be performed. While mea-
suring mobility, it is less gait-focused compared to
the EDSS and has been validated for use in persons
with MS to some extent.13,14 All information was
recorded in a systematic fashion by an experienced
and well-trained MS team for administrative pur-
poses. A more detailed description of the assess-
ments can be found elsewhere.10
Inclusion criteria
Inclusion into this study required the availability of
at least three complete, concomitant assessments of
RMI, 9-HPT, and EDSS, obtained over a period of at
least 2 years. Moreover, only persons with an EDSS
5.5 at the first in-patient rehabilitation stay were
analyzed. As shown in the flowchart in Figure 1,
further inclusion criteria pertained to completeness
of additional information (other than EDSS, RMI
and 9-HPT).
Statistical analysis
Baseline characteristics were analyzed descriptively
for the full population. The following characteristics
were compared at the first in-patient rehabilitation
stay (baseline): age, duration since MS diagnosis,
gender, type of MS (secondary, primary progressive,
unspecified progressive (chronic) form), EDSS,
RMI, 9-HPT, Multiple Sclerosis Severity Score
(MSSS).15,16 Age was transformed into restricted
Figure 1. Flowchart of persons with MS included in the
study.
EDSS: Expanded Disability Status Scale; RMI: Rivermead
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cubic splines because 1) the exact shape of the rela-
tionship between age and the different outcomes of
interest is generally unknown and 2) the factor age
was not the primary focus of study. Therefore, age
splines were just used for confounder adjustment but
not interpreted further.
Disability worsening in terms of RMI, 9-HPT, and
EDSS was determined according to the following
algorithm.17 Along the established progression cut-
offs, EDSS worsening was defined as an increase of
0.5 points from baseline, and confirmed by a second
EDSS measurement at least 6months later for per-
sons with a baseline EDSS 6 (and by 1 point for
baseline EDSS 5.5). For the 9-HPT, a 20% increase
in time (seconds) to complete the task was consid-
ered a worsening if confirmed at a second in-patient
stay at least 6months later.17 As no data on minimal
clinically important differences could be found in
the literature for RMI, a threshold of 2 units was
chosen, corresponding to the standard-deviation of
RMI changes over a one-year period found by anoth-
er observational study.18,19 The RMI increase also
needed to be confirmed on the subsequent visit.
Time-to-event methods were utilized to address
study goal 1 of describing the disability worsening
dynamics. Follow-up time started at the first in-
patient rehabilitation stay at the Berner clinic (base-
line) and ended at the occurrence of the confirmed
disability worsening (depending on the analyzed out-
come measure) or the last follow–up, whichever
occurred first. Time to worsening was assessed
using Kaplan-Meier plots and multivariable Cox
regression, investigating the following baseline char-
acteristics (age (splines), duration since MS diagno-
sis (¼disease duration), sex, type of MS, MSSS,
EDSS, use of disease-modifying treatment (DMT)).
Model selection followed an algorithm described
elsewhere, which is based on a selection criterion
of an Akaike Information Criterion score reduction
of 2.20 Based on this rule, disease duration was
eventually not included in the model. The propor-
tional hazards assumption was verified using
Schoenfeld residuals.
The second study goal aimed to investigate the over-
lap between EDSS-based disability worsening
(which is currently still considered the clinical gold
standard) and 9-HPT- and RMI-based disability
worsening. Descriptive statistics were employed to
characterize persons with and without EDSS-based
disability worsening. Additionally, the overlap of
disability worsening based on EDSS and other
outcome assessments was assessed in terms of sen-
sitivity, defined as the percentage of persons with
disability worsening based on 9-HPT or RMI as a
fraction of all persons with EDSS-based disability
worsening. Sensitivity was estimated both at time
of EDSS worsening and over the complete follow-
up period.
Analyses were conducted in Stata 13 (Stata Corp.,
College Station TX, USA.).
The re-usage of these data was approved by the
Ethics Committee Zurich (BASEC. 2017-00077),
who also issued a waiver for the retrospective
retrieval of informed consent.
Data availability
The data of this study are available from the corre-
sponding author on reasonable request.
Results
Out of 1931 persons with MS being treated at the
rehabilitation clinic between 1992 and 2015, 286
met all inclusion criteria for this study (Figure 1).
Of those, 61% were females and the median age was
51 years (Table 1). Per definition, these persons had
an advanced MS disease status: the median baseline
EDSS was 6.5, 72% of individuals were classified
with a secondary progressive MS, and at baseline the
median disease duration was 13 years. The median
follow-up duration was 6 years [interquartile range
(IQR) 4-10 years], and the median number of in-
patient rehabilitation stays was 5 [IQR 3–7], data
not shown.
Dynamics of disability worsening by different
outcome measures
In total 149 of 286 (52.1%) persons experienced
confirmed disability worsening as measured by
EDSS, 141 (49%, 9-HPT) and 153 (53%, RMI)
experienced confirmed disability worsening based
on the other two respective measurements. The
dynamics of worsening are illustrated in Figure 2.
Median disability worsening times were 5.2 years for
the EDSS, 5.8 years for the RMI, and 6.3 years for
the 9-HPT. The Kaplan-Meier curves in Figure 2
underscore these findings: whilst the RMI progresses
faster in the beginning and after about four years is
matched by the EDSS curve, the curve for 9-HPT
lags behind. The patterns in the late follow-up
(6 years) should not be overestimated however
due to the limited sample sizes.
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Additionally, factors associated with the three types
of disability worsening were investigated using mul-
tivariable Cox regression models (Table 2, univari-
able results are displayed in the Appendix, Table
S1). For the EDSS-worsening outcome, a higher
baseline EDSS was associated with a decrease in
worsening probability (Hazard Ratio HR 0.38 95%
confidence interval (CI) [0.27; 0.52]), whereas a
higher MSSS was associated with an increased risk
(HR 1.48, 95%-CI [1.30; 1.68]). Moreover, still
receiving DMT at baseline was also associated
with a risk decrease (HR 0.62, 95%-CI [0.40;
0.94]). In the RMI analysis, male gender (HR 1.48,
95%-CI [1.06; 2.08]) and higher MSSS (HR 1.12,
95%-CI [0.99; 1.27]) were associated with disability
worsening. When modelling disability worsening
based on 9-HPT, also male gender (HR 1.64,
95%-CI [1.15; 2.35]) and higher baseline MSSS
(HR 1.36, 95%-CI [1.18; 1.57]) were associated
with increasing risks for disability worsening.
Concordance of outcome measures with EDSS-based
disability worsening
As shown in Table 3, persons with EDSS-based dis-
ability worsening differed in several aspects from
persons without: they were less frequently female
(52% vs. 71%), somewhat younger at baseline
(median 51 vs. 53 years) and less frequently had a
secondary progressive MS (68% vs 77%). However,
median follow-up durations were also markedly dif-
ferent between the two groups, with a median of
5.2 years in the group without and 7.9 years in
those with EDSS-based disability worsening.
Further notable, the baseline MSSS was higher in
persons with worsening (median 7.39 compared
with 6.63 in persons without worsening), thus sug-
gesting an overall faster disease progression already
before baseline. Over the full observation period,
EDSS-defined disability worsening was also associ-
ated with a larger decrease of RMI scores (median
loss of 4 scores compared to 1 score among persons
without worsening), and a larger worsening of the
9-HPT (median increase of 17.5 s vs 5.75 s).
Table 1. Baseline characteristics of persons with MS included in the study.
All
N (%) 286 (100%)
Median age at baseline [IQR] 51 [43; 60]
Female sex 175 (61.19%)
Primary progressive MS 36 (12.59%)
Relapsing remitting MS 33 (11.54%)
Secondary progressive MS 207 (72.38%)
Unspecified progressive MS 10 (3.5%)
Receiving DMT 67 (23.43%)
Median year of first rehabilitation stay [IQR] 2001 [1998; 2004]
Baseline EDSS, median [IQR] 6.50 [6; 7]
Baseline MSSS, median [IQR] 7.03 [5.61; 8.23]
Baseline 9-HPT in seconds, median [IQR] 32.25 [26; 44.25]
Median years since MS onset at baseline, [IQR] 13 [7; 19]
Baseline RMI, median [IQR] 10 [7; 13]
Note: Baseline was defined as the first recorded in-patient rehabilitation stay.
EDSS: Expanded Disability Status Scale; DMT: disease-modifying treatment; IQR: inter-quartile
range; MSSS: Multiple Sclerosis Severity Score; RMI: Rivermead Mobility Index; 9-HPT: 9-Hole Peg
Test.
Figure 2. Kaplan-Meier plots of disability worsening as
measured by three outcome measures.
EDSS: Expanded Disability Status Scale; RMI: Rivermead
Mobility Index; 9-HPT: 9-Hole Peg Test.
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We further assessed the concordance of 9-HPT and
RMI-based disability worsening with EDSS-based
worsening. The results are shown in Table 4 and
illustrate that of 149 persons with EDSS worsening,
only 66 (44.3%) also had a confirmed 9-HPT wors-
ening at the time of EDSS worsening (sensitivity).
When assessing progression status at the last follow-
up visit, 97 of 149 persons (65.1%) also had a 9-
HPT worsening at some point during the observation
period. Corresponding numbers for the RMI were
higher, namely 83 (55.7%) concordance at time of
EDSS-worsening and 108 (72.5%) when consider-
ing the full observation period. Furthermore, of 141
persons with 9-HPT progression, 44 (31.2%)
showed no EDSS progression. For RMI, 45
(29.4%) showed no EDSS progression.
Discussion
Using a database of routinely collected rehabilitation
outcome measures from 286 persons with at least
three in-patient neurorehabilitation stays, this study
investigated the dynamics of disability worsening
using three different outcome measures, namely
EDSS, RMI, and 9-HPT. In particular, over a
median follow-up duration of 6 years, more than
half of all studied persons with MS had confirmed
disability worsening as measured by EDSS, 9-HPT,
and RMI. Our analysis further revealed that 44%
(9-HPT) and 56% (RMI) of PwMS with confirmed
EDSS-based disability worsening also had a worsen-
ing in the other respective measure at the time of
EDSS-based disability worsening. When considering
the full observation period, 65% (9-HPT), resp.
73% of persons with EDSS-based disability worsen-
ing also had a worsening in the other outcome mea-
sure. Moreover, MSSS at baseline turned out to be a
baseline predictor for disability worsening based on
any of the three outcome measures, thus confirming
the predictive properties of this score.
Overall, these findings provide novel insights into the
dynamics of disability worsening, as measured in dif-
ferent outcome domains, in a population that is rarely
studied. Comparisons with other databases indicate
that the studied population contains a substantial frac-
tion of persons with comparatively fast progressive
MS. For example, a study reported only around one
quarter of participants with impairments after a dis-
ease duration of 10-12 years that are as severe as in
the studied population.21 Along the same lines, a
recent analysis also comparing the dynamic of differ-
ent disability worsening measures included only
around one quarter of patients with impairments as
severe as in our population at baseline.22
Our findings fall well in line and extend previous
studies assessing the evolution of different outcome
assessment methods. The largest analysis performed
to date with over 12’000 MS trial participants cor-
roborates our observation that 9-HPT-based disabil-
ity worsening tends to lag behind EDSS-based
disability worsening definitions.17 Our study adds
to these findings by confirming these results in a
more impaired study population and over a longer
time scale.
Table 2. Multivariable Cox regression of EDSS, RMI or 9-HPT based disability worsening.
EDSS RMI 9-HPT
Age spline 1 1.02 [0.95; 1.10] 0.98 [0.92; 1.05] 1.01 [0.94; 1.09]
Age spline 2 1.00 [0.74; 1.35] 1.06 [0.80; 1.39] 0.84 [0.63; 1.14]
Age spline 3 0.87 [0.15; 5.12] 0.59 [0.12; 2.95] 2.78 [0.47; 16.34]
Age spline 4 1.28 [0.07; 23.01] 3.40 [0.24; 48.03] 0.24 [0.01; 4.30]
Male Gender 1.31 [0.93; 1.84] 1.48 [1.06; 2.08] 1.64 [1.15; 2.35]
MS type at baseline
Primary progressive MS Ref. Ref. Ref.
Relapsing remitting MS 1.05 [0.54; 2.03] 0.82 [0.42; 1.59] 0.82 [0.39; 1.71]
Secondary progressive MS 0.85 [0.53; 1.38] 0.86 [0.54; 1.37] 0.91 [0.56; 1.50]
Unspecified progressive MS 1.39 [0.57; 3.40] 0.63 [0.22; 1.85] 1.35 [0.53; 3.46]
Receiving DMT 0.62 [0.40; 0.94] 1.40 [0.95; 2.07] 0.85 [0.55; 1.32]
Baseline EDSS 0.38 [0.27; 0.52] 0.82 [0.61; 1.10] 0.76 [0.56; 1.02]
Baseline MSSS 1.48 [1.30; 1.68] 1.12 [0.99; 1.27] 1.36 [1.18; 1.57]
Note: All characteristics were assessed at baseline, that is, the first recorded in-patient rehabilitation stay.
DMT: disease-modifying treatments; EDSS: Expanded Disability Status Scale; MSSS: Multiple Sclerosis Severity
Score; RMI: Rivermead Mobility Index; 9-HPT: 9-Hole Peg Test.
Kaufmann et al.
www.sagepub.com/msjetc 5





N (%) 137 149
Median age at baseline [IQR] 53 [42; 62] 51 [43; 59]
Female sex 97 (70.8%) 78 (52.35%)
Median years since MS onset at baseline [IQR] 14 [8; 21] 11 [6; 18]
MS type at baseline
Primary progressive MS 15 (10.95%) 21 (14.09%)
Relapsing remitting MS 13 (9.49%) 20 (13.42%)
Secondary progressive MS 106 (77.37%) 101 (67.79%)
Unspecified progressive MS 3 (2.19%) 7 (4.7%)
Receiving disease modifying treatment at baseline 38 (27.74%) 29 (19.46%)
Median year of first rehabilitation stay [IQR] 2002 [1999; 2005] 2000 [1998; 2003]
Time to EDSS disability worsening – 3.12 [2.06; 4.98]
Total follow-up time in years, median [IQR] 5.20 [3.77; 8.16] 7.93 [5.11; 11.32]
Baseline MSSS, median [IQR] 6.63 [5.16; 8.24] 7.39 [5.69; 8.17]
Baseline EDSS, median [IQR] 6.50 [6; 7] 6 [6; 6.50]
Last available EDSS, median [IQR] 6.50 [6; 7.50] 7 [6.50; 8]
Within person EDSS difference between baseline and last
follow-up, median [IQR]
0 [0; 0] 1 [0.50; 1]
Baseline 9-HPT, median [IQR] 33 [26; 51.75] 31.75 [26; 39.75]
Last available 9-HPT, median [IQR] 44.75 [30; 67] 47.75 [34; 88.75]
Within person 9-HPT difference between baseline and last
follow-up, median [IQR]
5.75 [–0.75; 21] 17.50 [4.25; 34.75]
Baseline Rivermead Mobility Index, median [IQR] 10 [6; 13] 10 [7; 13]
Last available Rivermead Mobility Index, median [IQR] 7 [2; 11] 4 [1; 8]
Within person RMI difference between baseline and last
follow-up, median [IQR]
–1 [–4; 0] –4 [–8; –1]
Note: Status of characteristics was assessed at baseline; outcome measures were assessed as indicated either at baseline or the last follow-up.
EDSS: Expanded Disability Status Scale; IQR: inter-quartile range; MSSS: Multiple Sclerosis Severity Score; RMI: Rivermead Mobility
Index; 9-HPT: 9-Hole Peg Test.
Table 4. Correspondence of worsening status between EDSS and different outcome measures (9-HPT and RMI) at time of EDSS
















9-HPT at time of EDSS
worsening
83 44 66 93 44.3%
9-HPT over total follow-up 52 44 97 93 65.1%
RMI at time of EDSS
worsening
66 45 83 92 55.7%
RMI over total follow-up 41 45 108 92 72.5%
Note: Numbers in table reflect the number of individuals by worsening status.
EDSS: Expanded Disability Status Scale; OM: Outcome measure; RMI: Rivermead Mobility Index; 9-HPT 9-Hole Peg Test.
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Moreover, a different study found – while following
156 patients with a new diagnosis over 10 years –
that persons with non-relapsing disease courses
exhibited markedly faster deterioration of different
functional domains, particularly gait mobility, phys-
ical function or motor function.11 Our study was
unable to differentiate findings by MS form poten-
tially due to small numbers. Meanwhile, MSSS –
which is also responsive to MS type15 – emerged
as a potential predictor for disability impairments
in the time-to-event analysis. This latter finding
that MSSS was predictive for EDSS-, 9-HPT- and
RMI-defined disability worsening is noteworthy.
Our findings also extend studies of different out-
come measures in rehabilitation settings, which con-
firm the good psychometric properties and
responsiveness of RMI.18,19 In particular the study
by Baert et al found RMI to be sensitive to changes
in moderately to severely impaired patients.
Therefore, the changes in outcome measures
observed by this study are likely also clinically rel-
evant.19 Furthermore, because RMI also has a strong
gait component, the correspondence between EDSS-
and RMI-based disability worsening dynamics was
largely expected.15
Our study has strengths, but also limitations. To our
knowledge, our study includes one of the largest sam-
ples of more severely impaired persons with MS and
one of the longest follow-up durations of a study
performed in a rehabilitation setting to date. A further
strength is that the population seen at the Berner
Clinic – one of the major centers for MS rehabilita-
tion in Switzerland – is largely representative for per-
sons with MS attending in-patient rehabilitation in
general, being these treatments covered by the
Swiss basic health insurance. One important limita-
tion is that the data were collected mainly for admin-
istrative purposes and are dependent on whether and
when the clinic was attended. Moreover, certain var-
iables were only partially recorded, such as only
whether disease-modifying treatments were used,
but not the type nor duration. Further limitations
were imposed by changes in recorded outcome meas-
ures over the observation period. Because the
Functional Independence Measure (FIM), or the 25-
Foot Walk Test (25FTW) were not systematically
collected over the full study period, they could not
be assessed. Additionally, the differing length of
follow-up between the persons with
confirmed EDSS-progression and those without has
to be noted.
To conclude, this study describes long-term disabil-
ity worsening in persons with already advanced
impairments. Furthermore, MSSS seems to be infor-
mative for disability worsening risk stratification
even in persons with advanced MS and across dif-
ferent dimensions of body functioning.
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